Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Alzheimer's Disease

  Free Subscription


Articles published in Lancet Neurol

Retrieve available abstracts of 50 articles:
HTML format
Text format



Single Articles


    July 2019
  1. SELKOE D
    beta-secretase inhibitors for Alzheimer's disease: heading in the wrong direction?
    Lancet Neurol. 2019;18:624-626.
    PubMed     Text format    


    June 2019
  2. FRISONI GB, Alves IL, Barkhof F
    IDEAS becoming reality on the roadmap for biomarker validation in Alzheimer's disease.
    Lancet Neurol. 2019;18:519-520.
    PubMed     Text format    


    February 2019
  3. ARRANZ AM, De Strooper B
    The role of astroglia in Alzheimer's disease: pathophysiology and clinical implications.
    Lancet Neurol. 2019 Feb 19. pii: S1474-4422(18)30490.
    PubMed     Text format     Abstract available


  4. WALLACE LMK, Theou O, Godin J, Andrew MK, et al
    Investigation of frailty as a moderator of the relationship between neuropathology and dementia in Alzheimer's disease: a cross-sectional analysis of data from the Rush Memory and Aging Project.
    Lancet Neurol. 2019;18:177-184.
    PubMed     Text format     Abstract available


    January 2019
  5. IRWIN MR, Vitiello MV
    Implications of sleep disturbance and inflammation for Alzheimer's disease dementia.
    Lancet Neurol. 2019 Jan 17. pii: S1474-4422(18)30450.
    PubMed     Text format     Abstract available


    December 2018
  6. THE LANCET NEUROLOGY
    Will Europe be ready for the treatment of Alzheimer's disease?
    Lancet Neurol. 2018;17:1025.
    PubMed     Text format    


    November 2018

  7. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.
    Lancet Neurol. 2018 Nov 26. pii: S1474-4422(18)30403.
    PubMed     Text format     Abstract available


    October 2018
  8. BALIN BJ, Hudson AP
    Herpes viruses and Alzheimer's disease: new evidence in the debate.
    Lancet Neurol. 2018;17:839-841.
    PubMed     Text format    


    August 2018
  9. FORTEA J, Carmona-Iragui M, Benejam B, Fernandez S, et al
    Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
    Lancet Neurol. 2018 Aug 29. pii: S1474-4422(18)30285.
    PubMed     Text format     Abstract available


  10. RAFII MS
    Diagnostic biomarkers of Alzheimer's disease in Down syndrome.
    Lancet Neurol. 2018 Aug 29. pii: S1474-4422(18)30293.
    PubMed     Text format    


  11. CARMONA S, Zahs K, Wu E, Dakin K, et al
    The role of TREM2 in Alzheimer's disease and other neurodegenerative disorders.
    Lancet Neurol. 2018;17:721-730.
    PubMed     Text format     Abstract available



  12. Jo Barnes.
    Lancet Neurol. 2018;17:667.
    PubMed     Text format    


    July 2018
  13. MORGAN J
    No one knows what tomorrow might bring.
    Lancet Neurol. 2018;17:585.
    PubMed     Text format    


    June 2018
  14. KNUDSEN K, Fedorova TD, Hansen AK, Sommerauer M, et al
    In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study.
    Lancet Neurol. 2018 Jun 1. pii: S1474-4422(18)30162.
    PubMed     Text format     Abstract available


    May 2018
  15. DUFOUIL C, Glymour MM
    Prediction to prevention in Alzheimer's disease and dementia.
    Lancet Neurol. 2018;17:388-389.
    PubMed     Text format    


  16. ZIMMERMANN JF, Butler CR
    Accelerated long-term forgetting in asymptomatic APOE epsilon4 carriers.
    Lancet Neurol. 2018;17:394-395.
    PubMed     Text format    


    April 2018
  17. FRISONI GB, Jessen F
    One step towards dementia prevention.
    Lancet Neurol. 2018;17:294-295.
    PubMed     Text format    


    March 2018
  18. VAN DER LEE SJ, Wolters FJ, Ikram MK, Hofman A, et al
    The effect of APOE and other common genetic variants on the onset of Alzheimer's disease and dementia: a community-based cohort study.
    Lancet Neurol. 2018 Mar 16. pii: S1474-4422(18)30053.
    PubMed     Text format     Abstract available


  19. BALLARD C, Banister C, Khan Z, Cummings J, et al
    Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
    Lancet Neurol. 2018;17:213-222.
    PubMed     Text format     Abstract available


  20. SCHNEIDER LS
    Pimavanserin for patients with Alzheimer's disease psychosis.
    Lancet Neurol. 2018;17:194-195.
    PubMed     Text format    


    February 2018
  21. DUBOIS B, Epelbaum S, Nyasse F, Bakardjian H, et al
    Cognitive and neuroimaging features and brain beta-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Lancet Neurol. 2018 Feb 27. pii: S1474-4422(18)30029.
    PubMed     Text format     Abstract available


  22. WESTON PSJ, Nicholas JM, Henley SMD, Liang Y, et al
    Accelerated long-term forgetting in presymptomatic autosomal dominant Alzheimer's disease: a cross-sectional study.
    Lancet Neurol. 2018;17:123-132.
    PubMed     Text format     Abstract available


  23. REIMAN EM
    Long-term forgetting in preclinical Alzheimer's disease.
    Lancet Neurol. 2018;17:104-105.
    PubMed     Text format    


    January 2018
  24. GORDON BA, Blazey TM, Su Y, Hari-Raj A, et al
    Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study.
    Lancet Neurol. 2018 Jan 31. pii: S1474-4422(18)30028.
    PubMed     Text format     Abstract available


  25. TIJMS BM, Visser PJ
    Capturing the Alzheimer's disease pathological cascade.
    Lancet Neurol. 2018 Jan 31. pii: S1474-4422(18)30043.
    PubMed     Text format    


  26. AUGUSTIN K, Khabbush A, Williams S, Eaton S, et al
    Mechanisms of action for the medium-chain triglyceride ketogenic diet in neurological and metabolic disorders.
    Lancet Neurol. 2018;17:84-93.
    PubMed     Text format     Abstract available


    December 2017
  27. THE LANCET NEUROLOGY
    Alzheimer's disease: evolution of research diagnostic criteria.
    Lancet Neurol. 2017;16:945.
    PubMed     Text format    


    November 2017
  28. HALLIDAY G
    Pathology and hippocampal atrophy in Alzheimer's disease.
    Lancet Neurol. 2017;16:862-864.
    PubMed     Text format    


    October 2017
  29. SOININEN H, Solomon A, Visser PJ, Hendrix SB, et al
    24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial.
    Lancet Neurol. 2017 Oct 30. pii: S1474-4422(17)30332.
    PubMed     Text format     Abstract available


  30. YASSINE HN
    Targeting prodromal Alzheimer's disease: too late for prevention?
    Lancet Neurol. 2017 Oct 30. pii: S1474-4422(17)30372.
    PubMed     Text format    


    September 2017
  31. JOSEPHS KA, Dickson DW, Tosakulwong N, Weigand SD, et al
    Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study.
    Lancet Neurol. 2017 Sep 11. pii: S1474-4422(17)30284.
    PubMed     Text format     Abstract available


  32. DROUIN E, Drouin G
    The first report of Alzheimer's disease.
    Lancet Neurol. 2017;16:687.
    PubMed     Text format    


    August 2017
  33. FRISONI GB, Boccardi M, Barkhof F, Blennow K, et al
    Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers.
    Lancet Neurol. 2017;16:661-676.
    PubMed     Text format     Abstract available


  34. COLEY N, Andrieu S
    Lessons from the Multidomain Alzheimer Preventive Trial - Authors' reply.
    Lancet Neurol. 2017;16:586.
    PubMed     Text format    


  35. YASSINE HN, Schneider LS
    Lessons from the Multidomain Alzheimer Preventive Trial.
    Lancet Neurol. 2017;16:585-586.
    PubMed     Text format    


  36. ESCOTT-PRICE V, Jones L
    Genomic profiling and diagnostic biomarkers in Alzheimer's disease.
    Lancet Neurol. 2017;16:582-583.
    PubMed     Text format    


  37. ISAAC MT, Vamvakas S, Isaac MB
    Diagnostic biomarkers for Alzheimer's disease: a regulatory view.
    Lancet Neurol. 2017;16:580-581.
    PubMed     Text format    


    June 2017
  38. KIRBY T
    Eric Reiman: aiming to prevent Alzheimer's disease.
    Lancet Neurol. 2017 Jun 30. pii: S1474-4422(17)30216.
    PubMed     Text format    


    May 2017
  39. HARDY J
    Membrane damage is at the core of Alzheimer's disease.
    Lancet Neurol. 2017;16:342.
    PubMed     Text format    


    April 2017
  40. VOSSEL KA, Tartaglia MC, Nygaard HB, Zeman AZ, et al
    Epileptic activity in Alzheimer's disease: causes and clinical relevance.
    Lancet Neurol. 2017;16:311-322.
    PubMed     Text format     Abstract available


    February 2017
  41. THE LANCET NEUROLOGY
    Solanezumab: too late in mild Alzheimer's disease?
    Lancet Neurol. 2017;16:97.
    PubMed     Text format    


    January 2017
  42. SCHNEIDER L
    Alzheimer's disease and other dementias: update on research.
    Lancet Neurol. 2017;16:4-5.
    PubMed     Text format    


  43. ATTEMS J
    Alzheimer's disease pathology in synucleinopathies.
    Lancet Neurol. 2017;16:22-23.
    PubMed     Text format    


  44. IRWIN DJ, Grossman M, Weintraub D, Hurtig HI, et al
    Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis.
    Lancet Neurol. 2017;16:55-65.
    PubMed     Text format     Abstract available


    December 2016
  45. PANZA F, Logroscino G
    Anti-tau vaccine in Alzheimer's disease: a tentative step.
    Lancet Neurol. 2016 Dec 9. pii: S1474-4422(16)30340.
    PubMed     Text format    


  46. NOVAK P, Schmidt R, Kontsekova E, Zilka N, et al
    Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Lancet Neurol. 2016 Dec 9. pii: S1474-4422(16)30331.
    PubMed     Text format     Abstract available


    October 2016
  47. RYAN NS, Nicholas JM, Weston PS, Liang Y, et al
    Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer's disease: a case series.
    Lancet Neurol. 2016 Oct 21. pii: S1474-4422(16)30193.
    PubMed     Text format     Abstract available


  48. VAN DER FLIER WM
    Clinical heterogeneity in familial Alzheimer's disease.
    Lancet Neurol. 2016 Oct 21. pii: S1474-4422(16)30275.
    PubMed     Text format    


  49. TANG M, Ryman DC, McDade E, Jasielec MS, et al
    Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS).
    Lancet Neurol. 2016 Oct 21. pii: S1474-4422(16)30229.
    PubMed     Text format     Abstract available


    August 2016
  50. MORGAN J
    An orange and Alzheimer's disease?
    Lancet Neurol. 2016;15:911.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: